Skip to main content

MoneyWorks4Me

Aurobindo Pharma informs about disclosure

16 Feb 2023 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the Company’s wholly owned subsidiary, APL Healthcare Limited’s Unit I & III, an Orals (Tablets, Capsules and Soft gel Capsules) and Derma manufacturing facilities located at Jadcherla, Mahabub Nagar District, Telangana, which were inspected by the United States Food and Drug Administration from January 9 to January 18, 2023, have now been classified as Voluntary Action Indicated (VAI).

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1762.95
Dr. Reddys Labs. 1338.50
Cipla 1357.00
Lupin 1998.00
Zydus Lifesciences 1186.00
View more..